Grants per year
Fingerprint
Dive into the research topics where Maria Ascierto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 3 Active
-
Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L. & Spiliopoulou, P., May 2025, In: International Journal of Molecular Sciences. 26, 9, 4393.Research output: Contribution to journal › Review article › peer-review
Open Access -
Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis
Mendoza-Valderrey, A., Dettmann, E., Hanes, D., Kessler, D., Danilova, L., Rau, K., Quan, Y., Stern, S., Barkhoudarian, G., Bifulco, C., Margolin, K. A., Kolker, S. E. & Ascierto, M., May 2 2024, In: Articles, Abstracts, and Reports.Research output: Contribution to journal › Article
-
Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer
Mendoza-Valderrey, A., Choe, J., Kessler, D. M., Jimenez, G., Li, X., Kolker, S., Allen, W., Linehan, J. A., Twardowski, P. W. & Ascierto, M. L., Aug 2024, In: Cancer Medicine. 13, 15, e70088.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Patel, S. P., Alonso-Gordoa, T., Banerjee, S., Wang, D., Naidoo, J., Standifer, N. E., Palmer, D. C., Cheng, L. Y., Kourtesis, P., Ascierto, M. L., Das, M., Diamond, J. R., Hellmann, M. D. & Carneiro, B. A., Feb 2 2024, In: Journal for ImmunoTherapy of Cancer. 12, 2Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Garon, E. B., Spira, A. I., Goldberg, S. B., Chaft, J. E., Papadimitrakopoulou, V., Cascone, T., Antonia, S. J., Brahmer, J. R., Camidge, D. R., Powderly, J. D., Wozniak, A. J., Felip, E., Wu, S., Ascierto, M. L., Elgeioushi, N. & Awad, M. M., Aug 2023, In: Journal of Thoracic Oncology. 18, 8, p. 1094-1102 9 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations